Patents by Inventor Anand PANCHAL

Anand PANCHAL has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Constrained conditionally activated binding proteins
    Patent number: 12128102
    Abstract: The invention relates to COnditional Bispecific Redirected Activation constructs, or COBRAs, that are administered in an active pro-drug format. Upon exposure to tumor proteases, the constructs are cleaved and activated, such that they can bind both tumor target antigens (TTAs) as well as CD3, thus recruiting T cells expressing CD3 to the tumor, resulting in treatment.
    Type: Grant
    Filed: July 21, 2023
    Date of Patent: October 29, 2024
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Patrick Baeuerle, Robert B. DuBridge, Holger Wesche, Luke Evnin, Jeanmarie Guenot, Anand Panchal, Maia Vinogradova
  • THERAPEUTIC METHODS USING CONSTRAINED CONDITIONALLY ACTIVATED BINDING PROTEINS
    Publication number: 20240199744
    Abstract: The invention relates to COnditional Bispecific Redirected Activation constructs, or COBRAs, that are administered in an active pro-drug format. Upon exposure to tumor proteases, the constructs are cleaved and activated, such that they can bind both tumor target antigens (TTAs) as well as CD3, thus recruiting T cells expressing CD3 to the tumor, resulting in treatment.
    Type: Application
    Filed: April 6, 2022
    Publication date: June 20, 2024
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Chad Michael May, Robert B. DuBridge, Maia Vinogradova, Anand Panchal
  • CONSTRAINED CONDITIONALLY ACTIVATED BINDING PROTEINS
    Publication number: 20240199739
    Abstract: The invention relates to COnditional Bispecific Redirected Activation constructs, or COBRAs, that are administered in an active pro-drug format. Upon exposure to tumor proteases, the constructs are cleaved and activated, such that they can bind both tumor target antigens (TTAs) as well as CD3, thus recruiting T cells expressing CD3 to the tumor, resulting in treatment. In some embodiments, the tumor target antigen is B7H3.
    Type: Application
    Filed: May 16, 2023
    Publication date: June 20, 2024
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Chad May, Robert B. DuBridge, Maia Vinogradova, Anand Panchal
  • CONSTRAINED CONDITIONALLY ACTIVATED BINDING PROTEINS
    Publication number: 20240139317
    Abstract: The invention relates to COnditional Bispecific Redirected Activation constructs, or COBRAs, that are administered in an active pro-drug format. Upon exposure to tumor proteases, the constructs are cleaved and activated, such that they can bind both tumor target antigens (TTAs) as well as CD3, thus recruiting T cells expressing CD3 to the tumor, resulting in treatment.
    Type: Application
    Filed: July 21, 2023
    Publication date: May 2, 2024
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Chad May, Robert B. DuBridge, Maia Vinogradova, Anand Panchal
  • CONSTRAINED CONDITIONALLY ACTIVATED BINDING PROTEINS
    Publication number: 20230414752
    Abstract: The invention relates to COnditional Bispecific Redirected Activation constructs, or COBRAs, that are administered in an active pro-drug format. Upon exposure to tumor proteases, the constructs are cleaved and activated, such that they can bind both tumor target antigens (TTAs) as well as CD3, thus recruiting T cells expressing CD3 to the tumor, resulting in treatment.
    Type: Application
    Filed: July 21, 2023
    Publication date: December 28, 2023
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Chad May, Robert B. BuBridge, Maia Vinogradova, Anand Panchal
  • Constrained conditionally activated binding proteins
    Patent number: 11744893
    Abstract: The invention relates to COnditional Bispecific Redirected Activation constructs, or COBRAs, that are administered in an active pro-drug format. Upon exposure to tumor proteases, the constructs are cleaved and activated, such that they can bind both tumor target antigens (TTAs) as well as CD3, thus recruiting T cells expressing CD3 to the tumor, resulting in treatment.
    Type: Grant
    Filed: May 13, 2022
    Date of Patent: September 5, 2023
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Chad May, Robert B. DuBridge, Maia Vinogradova, Anand Panchal
  • Constrained conditionally activated binding proteins
    Patent number: 11744892
    Abstract: The invention relates to COnditional Bispecific Redirected Activation constructs, or COBRAs, that are administered in an active pro-drug format. Upon exposure to tumor proteases, the constructs are cleaved and activated, such that they can bind both tumor target antigens (TTAs) as well as CD3, thus recruiting T cells expressing CD3 to the tumor, resulting in treatment.
    Type: Grant
    Filed: May 13, 2022
    Date of Patent: September 5, 2023
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Chad May, Robert B. DuBridge, Maia Vinogradova, Anand Panchal
  • Single domain antigen binding domains that bind human Trop2
    Patent number: 11685780
    Abstract: The invention relates to COnditional Bispecific Redirected Activation constructs, or COBRAs, that are administered in an active pro-drug format. Upon exposure to tumor proteases, the constructs are cleaved and activated, such that they can bind both tumor target antigens (TTAs) as well as CD3, thus recruiting T cells expressing CD3 to the tumor, resulting in treatment. In some embodiments, the tumor target antigen is B7H3.
    Type: Grant
    Filed: March 5, 2020
    Date of Patent: June 27, 2023
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Chad May, Robert B. Dubridge, Maia Vinogradova, Anand Panchal
  • CONSTRAINED CONDITIONALLY ACTIVATED BINDING PROTEINS
    Publication number: 20220273795
    Abstract: The invention relates to COnditional Bispecific Redirected Activation constructs, or COBRAs, that are administered in an active pro-drug format. Upon exposure to tumor proteases, the constructs are cleaved and activated, such that they can bind both tumor target antigens (TTAs) as well as CD3, thus recruiting T cells expressing CD3 to the tumor, resulting in treatment.
    Type: Application
    Filed: May 13, 2022
    Publication date: September 1, 2022
    Inventors: Chad MAY, Robert B. DUBRIDGE, Maia VINOGRADOVA, Anand PANCHAL
  • CONSTRAINED CONDITIONALLY ACTIVATED BINDING PROTEINS
    Publication number: 20220273794
    Abstract: The invention relates to COnditional Bispecific Redirected Activation constructs, or COBRAs, that are administered in an active pro-drug format. Upon exposure to tumor proteases, the constructs are cleaved and activated, such that they can bind both tumor target antigens (TTAs) as well as CD3, thus recruiting T cells expressing CD3 to the tumor, resulting in treatment.
    Type: Application
    Filed: May 13, 2022
    Publication date: September 1, 2022
    Inventors: Chad MAY, Robert B. DUBRIDGE, Maia VINOGRADOVA, Anand PANCHAL
  • Constrained conditionally activated binding proteins
    Patent number: 11406710
    Abstract: The invention relates to COnditional Bispecific Redirected Activation constructs, or COBRAs, that are administered in an active pro-drug format. Upon exposure to tumor proteases, the constructs are cleaved and activated, such that they can bind both tumor target antigens (TTAs) as well as CD3, thus recruiting T cells expressing CD3 to the tumor, resulting in treatment.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: August 9, 2022
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Chad May, Robert B. Dubridge, Maia Vinogradova, Anand Panchal
  • CONDITIONALLY ACTIVATED BINDING PROTEINS CONTAINING Fc REGIONS AND MOIETIES TARGETING TUMOR ANTIGENS
    Publication number: 20220144949
    Abstract: Provided herein are compositions of conditionally activated binding proteins containing Fc regions such that the proteins target tumor antigens. Also provided are methods for coexpressing and purifying such conditionally activated binding proteins. Methods of treating cancer by administering the conditionally activated binding proteins to a patient are also described.
    Type: Application
    Filed: March 5, 2020
    Publication date: May 12, 2022
    Inventors: Robert B. DUBRIDGE, Anand PANCHAL
  • CONSTRAINED CONDITIONALLY ACTIVATED BINDING PROTEINS
    Publication number: 20200347132
    Abstract: The invention relates to COnditional Bispecific Redirected Activation constructs, or COBRAs, that are administered in an active pro-drug format. Upon exposure to tumor proteases, the constructs are cleaved and activated, such that they can bind both tumor target antigens (TTAs) as well as CD3, thus recruiting T cells expressing CD3 to the tumor, resulting in treatment. In some embodiments, the tumor target antigen is B7H3.
    Type: Application
    Filed: March 5, 2020
    Publication date: November 5, 2020
    Inventors: Chad MAY, Robert B. DUBRIDGE, Maia VINOGRADOVA, Anand PANCHAL
  • CONSTRAINED CONDITIONALLY ACTIVATED BINDING PROTEINS
    Publication number: 20190076524
    Abstract: The invention relates to COnditional Bispecific Redirected Activation constructs, or COBRAs, that are administered in an active pro-drug format. Upon exposure to tumor proteases, the constructs are cleaved and activated, such that they can bind both tumor target antigens (TTAs) as well as CD3, thus recruiting T cells expressing CD3 to the tumor, resulting in treatment.
    Type: Application
    Filed: September 7, 2018
    Publication date: March 14, 2019
    Inventors: Chad MAY, Robert B. Dubridge, Maia Vinogradova, Anand Panchal
  • INDUCIBLE BINDING PROTEINS AND METHODS OF USE
    Publication number: 20180134789
    Abstract: Provided herein are conditionally activated polypeptide constructs comprising a protease-activated domain binding to CD3, at least one half-life extension domain, and two or more domains binding to one or more target antigens. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such polypeptide constructs. Also disclosed are methods of using the disclosed polypeptide constructs in the prevention, and/or treatment diseases, conditions and disorders.
    Type: Application
    Filed: October 6, 2017
    Publication date: May 17, 2018
    Inventors: Patrick BAEUERLE, Robert B. DUBRIDGE, Holger WESCHE, Luke EVNIN, Jeanmarie GUENOT, Anand PANCHAL, Maia VINOGRADOVA